A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

Lancet

Volumn 368, Issue 9553, 2006, Pages 2125-2135

  MacArthur, Rodger D ^a   Novak, Richard M ^b   Peng, Grace ^c   Chen, Li ^c   Xiang, Ying ^c   Hullsiek, Katherine Huppler ^c   Kozal, Michael J ^d   van den Berg Wolf, Mary ^e   Henely, Christopher ^f   Schmetter, Barry ^g   Dehlinger, Marjorie ^h  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d YALE UNIVERSITY   (United States)

^e TEMPLE UNIVERSITY   (United States)

^f MERIDIAN HEALTH SYSTEM   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DIARRHEA; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; LYMPHOMA; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; VIROLOGY; VIRUS DETECTION; VOMITING;

EID: 33845396491     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69861-9     Document Type: Article

References (24)

1. Walmsley S., Bernstein B., King M., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (2002) 2039-2046
2. Staszewski S., Morales-Ramirez J., Tashima K., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341 (1999) 1865-1873
3. Olsen C., Gatell J., Ledergerber B., et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 19 (2005) 319-330
4. Robbins G., DeGrutolla V., Schafer R., et al. Comparison of sequential three-drug regimens as inital therapy for HIV-1 infection. N Engl J Med 249 (2003) 2293-2303
5. INITIO Trial International Coordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 368 (2006) 287-299
6. MacArthur R., Chen L., Mayers D., et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial. Control Clin Trials 22 (2001) 176-190
7. MacArthur R., Chen L., Peng G., et al. Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor or both in HIV-1 positive antiretroviral-naïve persons. HIV Clinical Trials 5 (2004) 361-370
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). http://www.aidsinfo.nih.gov/guidelines/ (accessed Sept 14, 2006)
9. MacArthur R., Perez G., Walmsley S., Baxter J., Mullin C., and Neaton J. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clinical Trials 6 (2005) 127-135
10. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 41 (1993) 1-19
11. Division of AIDS, NIH. Table for grading severity of adult adverse experiences (1998), National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
12. Johnson V., Brun-Vezinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 12 (2004) 119-124
13. Fitzmaurice G., Laird N., and Ware J. Applied longitudinal analysis (2004), John Wiley & Sons, Hoboken, NJ
14. Phillips A., Ledergerber B., Horban A., et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 18 (2004) 1795-1804
15. Marschner I., Collier A., Coombs R., et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 177 (1998) 40-47
16. van Leeuwen R., Katlama C., Murphy R., et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17 (2003) 987-999
17. Torti C., Maggliolo F., Patroni A., et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naïve HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother 56 (2005) 190-195
18. Friedl A., Ledergerber B., Flepp M., et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. AIDS 15 (2001) 1793-1800
19. Podzamczer D., Ferrer E., Consiglio E., et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (the COMBINE Study). Antiviral Therapy 7 (2002) 81-90
20. Raffanti S., Fusco J., Sherrill B., et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immun Defic Syndr 37 (2004) 1147-1154
21. Ledergerber B., Lundgren J., Walker A., et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364 (2004) 51-62
22. Phenix B., Angel J., Mandy F., et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 16 (2000) 559-567
23. Benito J., Lopez M., Martin J., et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 18 (2002) 1379-1388
24. Kozal MJ, Huppler Hullsiek K, MacArthur RD, et al. Initial virologic failure with HIV drug resistance and impact of resistance on disease progression and death for patients beginning PI, NNRTI or PI+NNRTI based strategies: the FIRST study. Abstracts of the XV International HIV Drug Resistance Workshop, June 13-17, 2006, Sitges, Spain.